You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: December 2019 to February 2026

AbstractFullPdf
Dec 2019440
Jan 202018183
Feb 202045452
Mar 202031312
Apr 2020434319
May 202080801
Jun 202036369
Jul 202059594
Aug 202039399
Sep 2020646420
Oct 202012012029
Nov 2020404016
Dec 202024249
Jan 2021363622
Feb 2021434329
Mar 202110610647
Apr 2021176189248
May 20219797106
Jun 2021505043
Jul 2021585644
Aug 2021979444
Sep 2021636437
Oct 2021828254
Nov 202110010051
Dec 2021848527
Jan 2022747635
Feb 2022899344
Mar 2022586742
Apr 2022788151
May 202210510757
Jun 2022555830
Jul 2022636522
Aug 2022828328
Sep 2022666329
Oct 2022949861
Nov 2022726649
Dec 2022798028
Jan 2023807925
Feb 2023768026
Mar 2023959632
Apr 2023555639
May 2023606225
Jun 2023777642
Jul 2023636149
Aug 2023535322
Sep 2023444418
Oct 2023757636
Nov 2023969745
Dec 2023717138
Jan 2024696958
Feb 2024545532
Mar 2024575767
Apr 2024848763
May 2024696838
Jun 2024605927
Jul 2024949534
Aug 2024747643
Sep 2024727350
Oct 2024616248
Nov 2024778045
Dec 202410810863
Jan 2025737045
Feb 202521221433
Mar 2025707053
Apr 2025798035
May 2025515341
Jun 2025394024
Jul 2025110
Nov 2025100
Feb 2026110
Total476148112547